Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 301–400 of 1,000
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
Decruyenaere, P., Offner, F. C., & Vandesompele, J. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00208-3 · Cited by 44
DLBCL 1L—What to Expect beyond R-CHOP?
Stegemann, M., Denker, S., & Schmitt, C. A. (2022) · Cancers · doi:10.3390/cancers14061453 · Cited by 44
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES
Roti, G., Sorrentino, C., & Cuneo, A. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.037 · Cited by 43
Xu-Monette, Z. Y., Zhang, H., Zhu, F., Tzankov, A., Bhagat, G., Visco, C., Dybkær, K., Chiu, A., Tam, W., Zu, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001949 · Cited by 43
Sangaletti, S., Iannelli, F., Zanardi, F., Cancila, V., Portararo, P., Botti, L., Vacca, D., Chiodoni, C., Napoli, A. D., Valenti, C. F., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103055 · Cited by 43
Current and emerging therapies for primary central nervous system lymphoma
Yuan, Y., Ding, T., Wang, S., Chen, H., Mao, Y. Q., & Chen, T. (2021) · Biomarker Research · doi:10.1186/s40364-021-00282-z · Cited by 43
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
Ishio, T., Kumar, S., Shimono, J., Daenthanasanmak, A., Dubois, S. P., Lin, Y., Bryant, B. R., Petrus, M. N., Bachy, E., Huang, D. W., et al. (2021) · Blood · doi:10.1182/blood.2021012734 · Cited by 43
Self-citationChiappella, A., Diop, F., Agostinelli, C., Novo, M., Nassi, L., Evangelista, A., Ciccone, G., Rocco, A. D., Martelli, M., Melle, F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17971 · Cited by 43
Yang, C., Cui, Y., Ren, X., Li, M., Yu, K., Shen, S., Jiang, H., Li, M., Zhang, X., Zhao, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901797 · Cited by 43
Thiéblemont, C., Chartier, L., Dührsen, U., Vitolo, U., Barrington, S. F., Zaucha, J. M., Vercellino, L., da Silva, M. G., Carvalho, I. P., Decazes, P., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006923 · Cited by 43
Wright, K., Weirather, J. L., Jiang, S., Kao, K. Z., Sigal, Y. M., Giobbie‐Hurder, A., Shipp, M. A., & Rodig, S. J. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009813 · Cited by 43
Diffuse Large B-Cell Lymphoma in the HIV Setting
Huguet, M., Navarro, J., Moltó, J., Ribera, J., & Tapia, G. (2023) · Cancers · doi:10.3390/cancers15123191 · Cited by 42
Extranodal lymphoma: pathogenesis, diagnosis and treatment
Yang, H., Xun, Y., Ke, C., Tateishi, K., & You, H. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00141-3 · Cited by 42
Wu, W., Miao, L., Lidong, Z., Zhu, Y., Mao, J., Cai, Z., Ji, Y., Wang, L., Wang, Y., & Jia, T. (2023) · Hematology · doi:10.1080/16078454.2023.2293514 · Cited by 42
Tumuluru, S., Godfrey, J. K., Cooper, A. B., Yu, J., Chen, X., MacNabb, B. W., Venkataraman, G., Zha, Y., Pelzer, B. W., Song, J. Y., et al. (2025) · Blood · doi:10.1182/blood.2024025355 · Cited by 42
Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications
Pratap, S., & Scordino, T. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.11.008 · Cited by 42
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
Alkodsi, A., Cervera, A., Zhang, K., Louhimo, R., Meriranta, L., Pasanen, A., Leivonen, S., Holte, H., Leppä, S., Lehtonen, R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0509-6 · Cited by 42
Villa, D. R., Tan, K. L., Steidl, C., Ben‐Neriah, S., Moosawi, M. A., Shenkier, T. N., Connors, J. M., Sehn, L. H., Savage, K. J. J., Scott, D. W., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000989 · Cited by 42
Self-citationPark, E., Chen, J., Moore, A., Mangolini, M., Santoro, A., Boyd, J. R., Schjerven, H., Ecker, V., Buchner, M., Williamson, J. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax9340 · Cited by 42
Tripodo, C., Zanardi, F., Iannelli, F., Mazzara, S., Vegliante, M. C., Morello, G., Napoli, A. D., Mangogna, A., Facchetti, F., Sangaletti, S., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101562 · Cited by 42
Yewdell, W. T., Kim, Y., Chowdhury, P., Lau, C. M., Smolkin, R. M., Belcheva, K. T., Fernandez, K. C., Cols, M., Yen, W.-F., Vaidyanathan, B., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.003 · Cited by 42
Deng, M., Xu-Monette, Z. Y., Pham, L. V., Wang, X., Tzankov, A., Fang, X., Zhu, F., Visco, C., Bhagat, G., Dybkær, K., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0466 · Cited by 42
Treating lymphoma is now a bit EZ-er
Morin, R. D., Arthur, S. E., & Assouline, S. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002773 · Cited by 42
From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy
Karagianni, P., Giannouli, S., & Voulgarelis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126321 · Cited by 42
Laurent, C., Adélaïde, J., Guillé, A., Tesson, B. M., Gat, E., Evrard, S., Escudié, F., Syrykh, C., Canioni, D., Fabiani, B., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001726 · Cited by 42
Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice
Weber, T., & Schmitz, R. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01155-2 · Cited by 42
Self-citationCarreras, J., Roncador, G., & Hamoudi, R. (2022) · Cancers · doi:10.3390/cancers14215318 · Cited by 42
Broséus, J., Hergalant, S., Vogt, J. A., Tausch, E., Kreuz, M., Mottok, A., Schneider, C., Dartigeas, C., Roos‐Weil, D., Quinquenel, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-34642-6 · Cited by 42
Self-citationDucharme, O., Beylot-Barry, M., Pham‐Ledard, A., Bohers, É., Viailly, P., Bandres, T., Faur, N., Frison, É., Vergier, B., Jardin, F., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.05.008 · Cited by 45
Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Hicks, A. M., Curry, M., Wagner‐Johnston, N. D., Karmali, R., et al. (2019) · Cancer · doi:10.1002/cncr.32526 · Cited by 42
Kazama, R., Miyoshi, H., Takeuchi, M., Miyawaki, K., Nakashima, K., Yoshida, N., Kawamoto, K., Yanagida, E., Yamada, K., Umeno, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14437 · Cited by 42
Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
Porpaczy, E. A., Wohlfarth, P., Königsbrügge, O., Rabitsch, W., Skrabs, C., Staber, P. B., Worel, N., Müllauer, L., Simonitsch‐Klupp, I., Kornauth, C., et al. (2021) · Cancers · doi:10.3390/cancers13225592 · Cited by 41
The dynamic functions of IRF4 in B cell malignancies
Maffei, R., Fiorcari, S., Atene, C. G., Martinelli, S., Mesini, N., Pilato, F., Lagreca, I., Barozzi, P., Riva, G., Nasillo, V., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00968-0 · Cited by 41
Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis
Kanavos, T., Birbas, E., Papoudou‐Bai, A., Hatzimichael, E. C., Kitsouli, A., Karpathiou, G., & Kanavaros, P. (2023) · Diseases · doi:10.3390/diseases11010042 · Cited by 41
Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma
Liu, N., Jiang, C., Yao, X., Fang, M., Qiao, X., Zhu, L., Yang, Z., Gao, X., Ji, Y., Niu, C., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00559-7 · Cited by 42
Quintanilla‐Martínez, L., Laurent, C., Soma, L. A., Ng, S., Climent, F., Ondrejka, S. L., Zamò, A., Wotherspoon, A. C., de Leval, L., Dirnhofer, S., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03590-x · Cited by 41
How I treat secondary CNS involvement by aggressive lymphomas
Alderuccio, J. P., Nayak, L., & Cwynarski, K. (2023) · Blood · doi:10.1182/blood.2023020168 · Cited by 41
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
Nayak, L., Bettegowda, C., Scherer, F., Galldiks, N., Ahluwalia, M. S., Baraniskin, A., von Baumgarten, L., Bromberg, J. E. C., Ferreri, A. J. M., Grommes, C., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae032 · Cited by 41
The Tumor Microenvironment of DLBCL in the Computational Era
Opinto, G., Vegliante, M. C., Negri, A., Skrypets, T., Loseto, G., Pileri, S. A., Guarini, A., & Ciavarella, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00351 · Cited by 41
Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma
Meriranta, L., Pasanen, A., Alkodsi, A., Haukka, J. K., Karjalainen‐Lindsberg, M., & Leppä, S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001727 · Cited by 41
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Modi, D., Potugari, B. R., & Uberti, J. P. (2021) · Cancers · doi:10.3390/cancers13225827 · Cited by 41
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
Vendramini, E., Bomben, R., Pozzo, F., Bittolo, T., Tissino, E., Gattei, V., & Zucchetto, A. (2022) · Cancers · doi:10.3390/cancers14030666 · Cited by 41
González‐Farré, B., Ramis-Zaldivar, J. E., de Anta, N. C., Rivas‐Delgado, A., Nadeu, F., Salmerón‐Villalobos, J., Enjuanes, A., Karube, K., Balagué, O., Cobo, F., et al. (2022) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001978 · Cited by 41
Self-citationWang, X., Nissen, M. D., Gracias, D., Kusakabe, M., Simkin, G. O., Jiang, A., Duns, G., Sarkozy, C., Hilton, L. K., Chavez, E. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34408-0 · Cited by 41
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 41
EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas
Otsuka, Y., Nishikori, M., Arima, H., Izumi, K., Kitawaki, T., Hishizawa, M., & Takaori-Kondo, A. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.006 · Cited by 40
Circulating tumor DNA in lymphoma: technologies and applications
Fu, L., Zhou, X., Zhang, X., Li, X., Zhang, F., Gu, H., & Wang, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01673-7 · Cited by 40
the Emed Demonstrator Project, Staiger, A. M., German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL), Altenbuchinger, M., Ziepert, M., Kohler, C., Horn, H., Huttner, M., Hüttl, K. S., Glehr, G., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0573-y · Cited by 40
Self-citationCyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells
Ramezani-Rad, P., Chen, C., Zhu, Z., & Rickert, R. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108403 · Cited by 40
Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma
Razzaghi, R., Agarwal, S., Kotlov, N., Plotnikova, O., Nomie, K. J., Huang, D. W., Wright, G. W., Smith, G., Li, M., Takata, K., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201173 · Cited by 40
Self-citationSzydłowski, M., Garbicz, F., Jabłońska, E., Górniak, P., Komar, D. N., Pyrzyńska, B., Bojarczuk, K., Prochorec‐Sobieszek, M., Szumera‐Ciećkiewicz, A., Rymkiewicz, G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1023 · Cited by 40
Lu, T., Zhang, J., Xu-Monette, Z. Y., & Young, K. H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00432-z · Cited by 40
Nowakowski, G. S., Feldman, T. A., Rimsza, L. M., Westin, J. R., Witzig, T. E., & Zinzani, P. L. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0208-6 · Cited by 40
Self-citationCastellino, A., Chiappella, A., LaPlant, B. R., Pederson, L., Gaïdano, G., Macon, W. R., Inghirami, G. G., Reeder, C. B., Tucci, A., King, R. L., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0145-9 · Cited by 39
The Need for a Consensus Next‐generation Sequencing Panel for Mature Lymphoid Malignancies
Sujobert, P., Bris, Y. L., de Leval, L., Gros, A., Merlio, J. P., Pastoret, C., Huet, S., Sarkozy, C., Davi, F., Callanan, M. B., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000169 · Cited by 39
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Tateishi, K., Miyake, Y., Kawazu, M., Sasaki, N., Nakamura, T., Sasame, J., Yoshii, Y., Ueno, T., Miyake, A., Watanabe, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2425 · Cited by 39
Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features
Pollari, M., Leivonen, S., & Leppä, S. (2021) · Cancers · doi:10.3390/cancers13164049 · Cited by 40
MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
Alcoceba, M., García‐Álvarez, M., Medina, A., Maldonado, R., González‐Calle, V., Chillón, C., Sarasquete, M. E., González, M., García‐Sánz, R., & Jiménez, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105570 · Cited by 39
A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020
Jiang, J., Lv, W., & Chen, N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105565 · Cited by 39
Xu, P., Shi, Z., Qian, Y., Cheng, S., Zhu, Y., Jiang, L., Li, J., Fang, H., Huang, H., Yi, H., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00123-4 · Cited by 39
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
Parrondo, R. D., Iqbal, M., von Roemeling, R., Roemeling, C. A. V., & Tun, H. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239082 · Cited by 39
Characterization of DLBCL with a PMBL gene expression signature
Duns, G., Viganò, E., Ennishi, D., Sarkozy, C., Hung, S. S., Chavez, E. A., Takata, K., Rushton, C. K., Jiang, A., Ben‐Neriah, S., et al. (2021) · Blood · doi:10.1182/blood.2020007683 · Cited by 39
Self-citationTargeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Scheich, S., Chen, J., Liu, J., Schnütgen, F., Enssle, J. C., Ceribelli, M., Thomas, C. J., Choi, J., Morris, V. M., Hsiao, T., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1401 · Cited by 38
Self-citationLuo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.007 · Cited by 38
Self-citationTranslational Advances in Oncogene and Tumor-Suppressor Gene Research
Stojchevski, R., Sutanto, E. A., Sutanto, R., Hadzi‐Petrushev, N., Mladenov, M. I., Singh, S. P., Sinha, J. K., Ghosh, S., Yarlagadda, B., Singh, K. K., et al. (2025) · Cancers · doi:10.3390/cancers17061008 · Cited by 38
Dai, Y., Kizhakeyil, A., Chihara, D., Li, X., Liu, Y., Sainz, T. P., Wilson, A., Henderson, J. M., Wiebe, D. S., Petrosyants, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02353-5 · Cited by 39
Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
Coccaro, N., Anelli, L., Zagaria, A., Perrone, T., Specchia, G., & Albano, F. (2020) · Cancers · doi:10.3390/cancers12010185 · Cited by 38
Vogelsberg, A., Steinhilber, J., Mankel, B., Federmann, B., Schmidt, J., Montes-Mojarro, I. A., Hüttl, K. S., Rodriguez-Pinilla, M. S., Baskaran, P., Nahnsen, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.254854 · Cited by 38
Self-citationXia, Z., Zhang, X., Liu, P., Zhang, R., Huang, Z., Li, D., Xiao, X., Wu, M. H., Ning, N., Zhang, Q., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03311-1 · Cited by 38
Schick, M., Zhang, L., Maurer, S., Maurer, H. C., Isaakidis, K., Schneider, L., Patra, U., Schunck, K., Rohleder, E., Hofstetter, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27704-8 · Cited by 38
Wang, X., Su, W., Gao, Y., Feng, Y., Wang, X., Chen, X., Hu, Y., Ma, Y., Ou, Q., Liang, D., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279908 · Cited by 38
Leung, W., Teater, M. R., Durmaz, C., Meydan, C., Chivu, A. G., Chadburn, A., Rice, E. J., Muley, A., Camarillo, J. M., Arivalagan, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1514 · Cited by 38
Application of precision medicine in clinical routine in haematology—Challenges and opportunities
Wästerlid, T., Cavelier, L. B., Haferlach, C., Konopleva, M. Y., Fröhling, S., Östling, P., Bullinger, L., Fioretos, T., & Smedby, K. E. E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13508 · Cited by 38
Ren, W., Wan, H., Own, S. A., Berglund, M., Wang, X., Yang, M., Li, X., Liu, D., Ye, X., Sonnevi, K., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02120-7 · Cited by 38
Deng, Q., Lakra, P., Gou, P., Yang, H., Meydan, C., Teater, M. R., Chin, C. R., Zhang, W., Dinh, T., Hussein, U. K., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.011 · Cited by 38
As the world turns, evolving lymphoma classifications–past, present and future
Swerdlow, S. H., & Cook, J. R. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.08.019 · Cited by 38
The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers
Velapasamy, S., Dawson, W. O., Young, L. S., Paterson, I. C., & Yap, L. F. (2018) · Cancers · doi:10.3390/cancers10080247 · Cited by 37
The role of HLA variation in lymphoma aetiology and survival
Zhong, C., Cozen, W., Bolanos, R., Song, J. Y., & Wang, S. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12911 · Cited by 37
McDonald, G., Chubukov, V., Coco, J., Truskowski, K., Narayanaswamy, R., Choe, S. E., Steadman, M., Artin, E., Padyana, A. K., Jin, L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0550 · Cited by 37
Manfroi, B., Grandis, M. D., Moreaux, J., Tabruyn, S. P., Mayol, J.-F., Quintero, M., Righini, C. A., Stürm, N., Aurrand‐Lions, M., & Huard, B. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004203 · Cited by 38
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Fukuhara, S., Oshikawa‐Kumade, Y., Kogure, Y., Shingaki, S., Kariyazono, H., Kikukawa, Y., Koya, J., Saito, Y., Tabata, M., Yoshifuji, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15427 · Cited by 37
CNS prophylaxis for diffuse large B-cell lymphoma
Eyre, T. A., Savage, K. J. J., Cheah, C. Y., El‐Galaly, T. C., Lewis, K. L., McKay, P., Wilson, M. R., Evens, A. M., Bobillo, S., Villa, D. R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00371-0 · Cited by 37
The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline
Fox, C. P., Chaganti, S., McIlroy, G., Barrington, S. F., Burton, C., Cwynarski, K., Eyre, T. A., Illidge, T., Kalakonda, N., Kühnl, A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19273 · Cited by 39
Lupino, L., Perry, T., Margielewska‐Davies, S., Hollows, R. J., Ibrahim, M., Care, M. A., Allegood, J. C., Tooze, R. M., Sabbadini, R. A., Reynolds, G. M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0478-9 · Cited by 37
Zhou, P., Blain, A. E., Newman, A. M., Zaka, M., Chagaluka, G., Adlar, F. R., Offor, U. T., Broadbent, C., Chaytor, L., Whitehead, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029546 · Cited by 37
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Schlager, S., Salomon, C., Olt, S., Albrecht, C., Ebert, A., Bergner, O., Wachter, J., Trapani, F., Gerlach, D., Voss, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27506 · Cited by 36
“Effective targeted therapies require the identification of essential oncogenic pathways within distinct DLBCL subgroups [4].”
BackgroundLuo, H. B., Liu, D., Liu, W., Jin, J., Bi, X., Zhang, P., Gu, J., Zheng, M., Xiao, M., Liu, X., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.11.012 · Cited by 36
Self-citationXu, X., Zhang, Y., Lu, Y., Zhang, X., Zhao, C., Wang, J., Guan, Q., Feng, Y., Gao, M., Yu, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2874 · Cited by 36
Self-citationMolecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Corcoran, S. R., Phelan, J. D., Choi, J., Shevchenko, G., Fenner, R. E., Yu, X., Scheich, S., Hsiao, T., Morris, V. M., Papachristou, E. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0802 · Cited by 36
Self-citationA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
Pirosa, M. C., Bruscaggin, A., di Bergamo, L. T., Salehi, M., Jauk, F., Forestieri, G., Bocchetta, S., Piffaretti, D., Moia, R., Cristaldi, V., et al. (2025) · Blood · doi:10.1182/blood.2024027355 · Cited by 36
Sasi, B. K., Martines, C., Xerxa, E., Porro, F., Kalkan, H., Fazio, R., Turkalj, S., Bojnik, E., Pyrzyńska, B., Stachura, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0442-8 · Cited by 36
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
Ribeiro, M. L., Reyes-Garau, D., Armengol, M., Fernández-Serrano, M., & Roué, G. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00986 · Cited by 36
Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma
Lee, J., Kim, B., Lee, H., Park, H., Byeon, S. H., Choi, J. R., Lee, S. C., Lee, S., & Lee, C. S. (2020) · Haematologica · doi:10.3324/haematol.2019.233783 · Cited by 36
Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas
Drees, E. E. E., & Pegtel, D. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.06.003 · Cited by 36
Crouch, S., Painter, D., Barrans, S., Roman, E., Beer, P. A., Cooke, S. L., Glover, P., Hoppe, S. V., Webster, N., Lacy, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005284 · Cited by 36
Self-citationMinderman, M., Lantermans, H. C., Grüneberg, L. J., Cillessen, S. A. G. M., Bende, R. J., van Noesel, C. J. M., Kersten, M. J., Pals, S. T., & Spaargaren, M. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00809-7 · Cited by 38
Landsburg, D. J., Morrissette, J. J. D., Nasta, S. D., Barta, S. K., Schuster, S. J., Svoboda, J., Chong, E. A., & Bagg, A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011384 · Cited by 36
Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35
Diagnostic methods for primary vitreoretinal lymphoma: A systematic review
Huang, R. S., Mihalache, A., Popovic, M. M., Cruz-Pimentel, M., Pandya, B. U., Muni, R. H., & Kertes, P. J. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.12.001 · Cited by 35
Phelan, J. D., Scheich, S., Choi, J., Wright, G. W., Häupl, B., Young, R. M., Rieke, S. A., Pape, M., Ji, Y., Urlaub, H., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.019 · Cited by 35
Self-citation
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.